Karyopharm Therapeutics: Promising Potential With 3 Ongoing Phase 3 Studies But Risky

Cancer In The Blood


Thesis overview

Karyopharm’s (NASDAQ:KPTI) guide candidate is selinexor, which has a novel mechanism of action. It acts as a selective inhibitor of nuclear export by binding to exporting 1 (XPO1). KPTI has been the leader in targeting this pathway and has successfully developed

Source link